Copied
 
 
Formål
HistorikStartStop
Selskabets formål er at investere i ejerandele eller i øvrigt anbringe midler i et eller flere erhvervsdrivende biomedicinske eller bioteknologiske selskaber fortrinsvis i Norden, England, Irland, Frankrig, Tyskland, Holland, Belgien og Luxembourg. Selskabet kan eje såvel majoritets- som minoritetsposter i sådanne selskaber. Selskabet kan anbringe ledig likviditet i statsobligationer med kort løbetid og i kontante indskud i pengeinstitutter17.12.200925.03.2021
Virksomheden har ikke ændret Formål i sin levetid.
Ingen nuværende registrering.
Status
HistorikStartStop
OPLØST EFTER FRIVILLIG LIKVIDATION25.03.202125.03.2021
UNDER FRIVILLIG LIKVIDATION15.07.201624.03.2021
NORMAL30.01.200114.07.2016
Ingen nuværende registrering.
Branche
HistorikStartStop
Ventureselskaber og kapitalfonde (643040)01.01.200825.03.2021
Ventureselskaber (652325)01.01.200331.12.2007
Investeringsselskaber (652320)01.02.200131.12.2002
Uoplyst (980000)30.01.200131.01.2001
Ingen nuværende registrering.
Revision
HistorikStartStop
false30.01.200125.03.2021
Virksomheden har ikke ændret Revision i sin levetid.
Ingen nuværende registrering.
Revisor
Ingen nuværende registrering.
Form
HistorikStartStop
7030.01.200125.03.2021
Virksomheden har ikke ændret Form i sin levetid.
Ingen nuværende registrering.
Kontakt
Ingen nuværende registrering.
Ingen historik.
Telefon
HistorikStartStop
3391905122.02.200107.02.2002
Virksomheden har ikke ændret Telefon i sin levetid.
Ingen nuværende registrering.
Navne
Ingen nuværende registrering.
Binavne
HistorikStartStop
BI BIOMEDICAL VENTURE III LTD. P/S30.01.200117.12.2009
BI BIOMEDICINSK VENTURE III LTD. P/S30.01.200118.06.2002
Ingen nuværende registrering.
Tegningsregel
HistorikStartStop
Virksomheden tegnes af en likvidator15.07.201625.03.2021
Selskabet tegnes af komplementaren eller af to medlemmer af bestyrelsen17.12.200914.07.2016
Ingen nuværende registrering.
Ansatte
16.05.2024
Ingen historik.
Kapital
16.05.2024
Fra årsrapport
Type af revisorbistand:Revisionspåtegning
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision):We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditor’s responsibilities for the audit of the financial statements section of this auditor’s report. We are independent of the Fund in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Konklusion (revision):We have audited the financial statements of P/S Sunstone Biomedicinsk Venture III in liquidation for the financial year 01. 01. 2019 - 31. 12. 2019, which comprise the income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial statements Act. In our opinion, the financial statements give a true and fair view of the Fund’s financial position at 31. 12. 2019 and of the results of its operations and cash flows for the financial year 01. 01. 2019 - 31. 12. 2019 in accordance with the Danish Financial statements Act.
Udtalelse om ledelsesberetningen (revision):Liquidator is responsible for the management commentary. Our opinion on the financial statements døs not cover the management commentary, and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the management commentary and, in doing so, consider whether the management commentary is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether the management commentary provides the information required under the Danish Financial statements Act. Based on the work we have performed, we conclude that the management commentary is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial statements Act. We did not identify any material misstatement of the management commentary.
Bibranche
Ingen nuværende registrering.
Ingen historik.
Børsnoteret
16.05.2024
Ingen nuværende registrering.
Ingen historik.
Hjemmeside
16.05.2024
Ingen nuværende registrering.
Ingen historik.